• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

    2/12/24 10:06:24 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    SC 13G/A 1 tm245889d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    Brainstorm Cell Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.00005 par value

    (Title of Class of Securities)

     

    10501E 201

    (CUSIP Number)

     

    Febuary 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)
    x   Rule 13d-1(c)
    ¨   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 10501E 201

     

    1.  

    Names of Reporting Persons

    Kevin D. Ness 

     

    2.   Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)   ¨
        (b)  

    ¨

     

    3.  

    SEC Use Only

     

    4.   Citizenship or Place of Organization
    Canada 

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

     

    6.

    Shared Voting Power

    3,060,000 (1)

     

    7.

    Sole Dispositive Power

    0

     

    8.

    Shared Dispositive Power

    3,060,000 (1)

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,060,000 (1) 

     

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    6.25% (2)

     

    12.  

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Consists of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power.

     

    (2)

    Percentage of class is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    1

     

    CUSIP No. 10501E 201

     

    Item 1.    
      (a) Name of Issuer
       

    Brainstorm Cell Therapeutics Inc.

     

      (b) Address of Issuer's Principal Executive Offices
        1325 Avenue of Americas, 28th Floor, New York, NY 10019
         
    Item 2.    
      (a) Name of Persons Filing
        Kevin D. Ness (the “Reporting Person”)
         
      (b) Address of Principal Business Office or, if none, Residence
       

    The principal business address for the Reporting Person is:

    2121 N. California Blvd., Suite 610

    Walnut Creek, CA 94596

     

      (c) Citizenship
       

    The Reporting Person is a citizen of Canada.

     

      (d) Title of Class of Securities
       

    Common Stock, $0.00005 par value

     

      (e) CUSIP No.
       

    10501E 201

     

    Item 3.   If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
        Not Applicable

     

    Item 4.

     

    Ownership

       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
    Item 1.

     

      (a)

    Amount beneficially owned:

    3,060,000 shares of Common Stock

     

      (b) Percent of class: 6.25%

     

      (c) Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    0 shares of Common Stock

     

      (ii)

    Shared power to vote or to direct the vote:

    3,060,000 shares

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    0 shares of Common Stock

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    3,060,000 shares

     

    2

     

    CUSIP No. 10501E 201

     

    The securities reported above consist of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power. The reported beneficial ownership percentage is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    Item 5. Ownership of Five Percent or Less of a Class
      Not Applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
      Not Applicable.
       
    Item 10. Certification
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.

     

    3

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: Febuary 8, 2024

     

      Kevin D. Ness
           
      By:    /s/ Kevin D. Ness
          Name: Kevin D. Ness

     

    4

     

    Get the next $BCLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainstorm Cell upgraded by Maxim Group

      Maxim Group upgraded Brainstorm Cell from Hold to Buy

      2/5/21 8:55:41 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

      2/4/21 1:51:23 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care